Ras protein signalling

Seminars in Immunology

Volumn 12, Issue 1, 2000, Pages 63-73

  Olson, Michael F ^a   Marais, Richard ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cell transformation; Ras proteins; Signalling

Indexed keywords

ISOPROTEIN; RAS PROTEIN;

APOPTOSIS; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELL TRANSFORMATION; HUMAN; NERVE CONDUCTION; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION;

EID: 0033996413     PISSN: 10445323     EISSN: None     Source Type: Journal    
DOI: 10.1006/smim.2000.0208     Document Type: Article

References (102)

1. Barbacid M. Ras genes. Annu Rev Biochem. 56:1987;779-827.
2. Bos JL. Ras oncogenes in human cancer. Cancer Res. 49:1989;4682-4689.
3. Downward J. Control of Ras activation. Cancer Surv. 27:1996;87-100.
4. Bos JL. Ras-like GTPases. Biochim Biophys Acta. 1333:1997;19-31.
5. Downward J, Graves JD, Warne PH, Rayter S, Cantrell DA. Stimulation of p21Ras upon T-cell activation. Nature. 346:1990;719-723.
6. Swan KA et al. Involvement of p21Ras distinguishes positive and negative selection in thymocytes. EMBO J. 14:1995;276-285.
7. Fields PE, Gajewski TF, Fitch FW. Blocked Ras activation in anergic CD4+ T cells. Science. 271:1996;1276-1278.
8. Rapoport MJ, Lazarus AH, Jaramillo A, Speck E, Delovitch TL. Thymic T cell anergy in autoimmune nonobese diabetic mice is mediated by deficient T cell receptor regulation of the pathway of p21Ras activation. J Exp Med. 177:1993;1221-1226.
9. Iritani BM, Forbush KA, Farrar MA, Perlmutter RM. Control of B cell development by Ras-mediated activation of Raf. EMBO J. 16:1997;7019-7031.
10. Jin DI, Jameson SB, Reddy MA, Schenkman D, Ostrowski MC. Alterations in differentiation and behavior of monocytic phagocytes in transgenic mice that express dominant suppressors of ras signaling. Mol Cell Biol. 15:1995;693-703.
11. Weijzen S, Velders MP, Kast WM. Modulation of the immune response and tumor growth by activated Ras. Leukemia. 13:1999;502-513.
12. Constantinidou M et al. Codon 12 Ras mutations in patients with myelodysplastic syndrome: incidence and prognostic value. Ann Hematol. 74:1997;11-14.
13. Padua RA et al. RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia. 12:1998;887-892.
14. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 9:1997;180-186.
15. Tan PB, Kim SK. Signaling specificity: the RTK/RAS/MAP kinase pathway in metazoans. Trends Genet. 15:1999;145-149.
16. Sternberg PW, Han M. Genetics of RAS signaling in C. elegans. Trends Genet. 14:1998;466-472.
17. Vojtek AB, Der CJ. Increasing complexity of the Ras signaling pathway. J Biol Chem. 273:1998;19925-19928.
18. Maher J, Baker DA, Manning M, Dibb NJ, Roberts IA. Evidence for cell-specific differences in transformation by N-, H- and K-Ras. Oncogene. 11:1995;1639-1647.
19. Thompson TA, Kim K, Gould MN. Harvey Ras results in a higher frequency of mammary carcinomas than Kirsten Ras after direct retroviral transfer into the rat mammary gland. Cancer Res. 58:1998;5097-5104.
20. Umanoff H, Edelmann W, Pellicer A, Kucherlapati R. The murine N-Ras gene is not essential for growth and development. Proc Natl Acad Sci USA. 92:1995;1709-1713.
21. Koera K et al. K-Ras is essential for the development of the mouse embryo. Oncogene. 15:1997;1151-1159.
22. Johnson L et al. K-Ras is an essential gene in the mouse with partial functional overlap with N-Ras. Genes Dev. 11:1997;2468-2481.
23. Marshall CJ. Specificity of receptor tyrosine kinase signalling: transient versus sustained extracellular signal- regulated kinase activation. Cell. 80:1995;179-185.
24. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic Ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:1997;593-602.
25. A. Sewing, B. Wiseman, A. C. Lloyd, H. Land. High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. Mol Cell Biol. 17:1997;5588-5597.
26. Olson MF, Paterson HF, Marshall CJ. Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. Nature. 394:1998;295-299.
27. Pawson T. Tyrosine kinase signalling pathways. Princess Takamatsu Symp. 24:1994;303-322.
28. Kouhara H et al. A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway. Cell. 89:1997;693-702.
29. Hadari YR, Kouhara H, Lax I, Schlessinger J. Binding of Shp2 tyr osine phosphatase to FRS2 is essential for fibro- blast growth factor-induced PC12 cell differentiation. Mol Cell Biol. 18:1998;3966-3973.
30. Van Vactor D, O'Reilly AM, Neel BG. Genetic analysis of protein tyrosine phosphatases. Curr Opin Genet Dev. 8:1998;112-126.
31. Duffy JB, Perrimon N. The torso pathway in Drosophila: lessons on receptor tyrosine kinase signaling and pattern formation. Dev Biol. 166:1994;380-395.
32. Cleghon V et al. Drosophila terminal structure development is regulated by the compensatory activities of positive and negative phosphotyrosine signaling sites on the Torso RTK. Genes Dev. 10:1996;566-577.
33. Cleghon V et al. Opposing actions of CSW and RasGAP modulate the strength of Torso RTK signaling in the Drosophila terminal pathway. Mol Cell. 2:1999;719-727.
34. Rudd CE. Adaptors and molecular scaffolds in immune cell signaling. Cell. 96:1999;5-8.
35. Cantrell D. The real LAT steps forward. Trends Cell Biol. 8:1998;180-182.
36. Huyer G, Alexander DR. Immune signalling: SHP-2 docks at multiple ports. Curr Biol. 9:1999;129-132.
37. Neel BG. Role of phosphatases in lymphocyte activation. Curr Opin Immunol. 9:1997;405-420.
38. Gu H, Pratt JC, Burakoff SJ, Neel BG. Cloning of p97/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation. Mol Cell. 2:1998;729-240.
39. Vincent S, Wilson R, Coelho C, Affolter M, Leptin M. The Drosophila protein Dof is specifically required for FGF signaling. Mol Cell. 2:1998;515-525.
40. Casci T, Vinós J, Freeman M. Sprouty, an intracellular inhibitor of Ras signaling. Cell. 96:1999;655-665.
41. Tefft JD et al. Conserved function of mSpry-2, a murine homolog of Drosophila sprouty, which negatively modulates respiratory organogenesis. Curr Biol. 9:1999;219-222.
42. Hancock JF, Cadwallader K, Marshall CJ. Methylation and proteolysis are essential for efficient membrane binding of prenylated p21K-ras(B). EMBO J. 10:1991a;641-646.
43. Hancock JF, Cadwaller K, Paterson H, Marshall CJ. A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of Ras proteins. EMBO J. 10:1991b;4033-4039.
44. Hancock JF, Paterson H, Marshall CJ. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21Ras to the plasma membrane. Cell. 63:1990;133-139.
45. Jacobson, K, Dietrich, C, 1999, 87, 91.
46. Brown DA, London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol. 14:1998;111-136.
47. Magee T, Marshall C. New insights into the interaction of Ras with the plasma membrane. Cell. 98:1999;9-12.
48. Roy S et al. Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat Cell Biol. 1:1999;98-105.
49. Schmid, S, Sternberg, P, Caveolin, cholesterol and Ras signalling. Nat Cell Biol, 1, E35-, E37.
50. Furuchi T, Anderson RG. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J Biol Chem. 273:1998;21099-21104.
51. Hatanaka M et al. Expression of caveolin-1 in human T cell leukemia cell lines. Biochem Biophys Res Commun. 253:1998;382-387.
52. Harder T, Simons K. Clusters of glycolipid and glycosylphosphatidylinositol-anchored proteins in lymphoid cells: accumulation of actin regulated by local tyrosine phosphorylation. Eur J Immunol. 29:1999;556-562.
53. Xavier R, Brennan T, Li Q, McCormack C, Seed B. Membrane compartmentation is required for efficient T cell activation. Immunity. 8:1998;723-732.
54. Schroeder RJ, Ahmed SN, Zhu Y, London E, Brown DA. Cholesterol and sphingolipid enhance the Triton X-100 insolubility of glycosylphosphatidylinositol-anchored proteins by promoting the formation of detergent-insoluble ordered membrane domains. J Biol Chem. 273:1998;1150-1157.
55. Volonté D et al. Flotillins/cavatellins are differentially expressed in cells and tissues and form a hetero-oligomeric complex with caveolins in vivo. Characterization and epitope-mapping of a novel flotillin-1 monoclonal antibody probe. J Biol Chem. 274:1999;12702-12709.
56. Yan J, Roy S, Apolloni A, Lane A, Hancock JF. Ras isoforms vary in their ability to activate Raf-1 and phosphoinositide 3-kinase. J Biol Chem. 273:1998;24052-24056.
57. Voice JK, Klemke RL, Le A, Jackson JH. Four human ras homologs differ in their abilities to activate Raf-1, induce transformation, and stimulate cell motility. J Biol Chem. 274:1999;17164-17170.
58. Hamilton M, Wolfman A. Ha-Ras and N-Ras regulate MAPK activity by distinct mechanisms in vivo. Oncogene. 16:1998;1417-1428.
59. Morrison DK, Cutler REJ. The complexity of Raf-1 regulation. Curr Opin Cell Biol. 9:1997;174-179.
60. Fabian JR, Daar IO, Morrison DK. Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol Cell Biol. 13:1993;7170-7179.
61. Diaz B et al. Phosphorylation of Raf-1 serine 338-serine 339 is an essential regulatory event for Ras-dependent activation and biolgical signalling. Mol Cell Biol. 17:1997;4509-4516.
62. Mason CS et al. Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J. 18:1999;2137-2148.
63. Wixler V, Smola U, Schuler M, Rapp U. Differential regulation of Raf isozymes by growth versus differentiation inducing factors in PC12 pheochromocytoma cells. Febs Lett. 385:1996;131-137.
64. Traverse S, Gomez N, Paterson H, Marshall CJ, Cohen P. Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J. 288:1992.
65. White MA et al. Multiple Ras functions can contribute to mammalian cell transformation. Cell. 80:1995;533-541.
66. Rodriguez-Viciana P et al. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 89:1997;457-467.
67. Joneson T, White MA, Wigler MH, Bar-Sagi D. Stimulation of membrane ruffling and MAP kinase activation by distinct effectors of Ras. Science. 271:1996;810-812.
68. KhosraviFar R et al. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol. 16:1996;3923-3933.
69. Kauffmann-Zeh A et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature. 385:1997;544-548.
70. Genot E, Reif K, Beach S, Kramer I, Cantrell D. p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes. Oncogene. 17:1998;1731-1738.
71. Malumbres M, Pellicer A. Ras pathways to cell cycle control and cell transformation. Front Biosci. 6:1998;887-912.
72. Jones MK, Jackson JH. Ras-GRF activates Ha-Ras, but not N-Ras o r K-Ras 4B, protein in vivo. J Biol Chem. 273:1998;1782-1787.
73. Orita S et al. Comparison of kinetic properties between tw o mammalian ras p21 GDP/GTP exchange proteins, Ras guanine nucleotide-releasing factor and smg GDP dissociation stimulation. J Biol Chem. 268:1993;25542-25546.
74. McCormick F, Martin GA, Clark R, Bollag G, Polakis P. Regulation of Ras p21 by GTPase activating proteins. Cold Spring Harbor Symp Quant Biol. 56:1991;237-241.
75. Xu G et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell. 62:1990a;599-608.
76. Maekawa M et al. A novel mammalian Ras GTPase-activating protein which has phospholipid-binding and Btk homology regions. Mol Cell Biol. 14:1994;6879-6885.
77. Kim JH, Liao D, Lau LF, Huganir RL. SynGAP: a synaptic RasGAP that associates with the PSD-95/SAP90 protein family. Neuron. 20:1998;683-691.
78. Bollag G, McCormick F. Differential regulation of RasGAP and neurofibromatosis gene product activities. Nature. 351:1991;576-580.
79. Taylor S, Shalloway D. Cell cycle-dependent activation of Ras. Curr Biol. 6:1996;1621-1627.
80. de Rooij J, Bos J. Minimal Ras-binding domain of Raf1can be used as an activation-specific probe for Ras. Oncogene. 14:1997;623-625.
81. Kornfeld K, Hom DB, Horvitz HR. The ksr-1 gene encodes a novel protein kinase involved in Ras-mediated signaling in C. elegans. Cell. 83:1995;903-913.
82. Sundaram M, Han M. The C. elegans KSR-1 gene encodes a novel Raf-related kinase involved in Ras-mediated signal transduction. Cell. 83:1995;889-901.
83. Therrien M et al. KSR, a novel protein kinase required for RAS signal transduction. Cell. 83:1995;879-888.
84. Zhang Y et al. Kinase suppressor of Ras is ceramide-activated protein kinase. Cell. 89:1997;63-72.
85. Michaud NR et al. KSR stimulates Raf-1 activity in a kinase-independent manner. Proc Natl Acad Sci USA. 94:1997;12792-12796.
86. Joneson T et al. Kinase suppressor of Ras inhibits the activation of extracellular ligand-regulated (ERK) mitogen-activated protein (MAP) kinase by growth factors, activated Ras, and Ras effectors. J Biol Chem. 273:1998;7743-7748.
87. Yu W, Fantl WJ, Harrowe G, Williams LT. Regulation of the MAP kinase pathway by mammalian Ksr through direct interaction with MEK and ERK. Curr Biol. 8:1998;56-64.
88. Denouel-Galy A et al. Murine KSR interacts with MEK and inhibits Ras-induced transformation. Curr Biol. 8:1998;46-55.
89. Therrien M, Michaud NR, Rubin GM, Morrison DK. KSR modulates signal propagation within the MAPK cascade. Genes Dev. 10:1996;2684-2695.
90. Cacace AM et al. Identification of constitutive and Ras-inducible phosphorylation sites of KSR: implications for 14-3-3 binding, mitogen-activated protein kinase binding, and KSR overexpression. Mol Cell Biol. 19:1999;229-240.
91. Therrien M, Wong AM, Rubin GM. CNK, a RAF-binding multidomain protein required for RAS signaling. Cell. 95:1998;343-353.
92. Sieburth DS, Sun Q, Han M. SUR-8, a conserved Ras-binding protein with leucine-rich repeats, positively regulates Ras-mediated signaling in C. elegans. Cell. 94:1998;119-130.
93. Selfors LM, Schutzman JL, Borland CZ, Stern MJ. soc-2 encodes a leucine-rich repeat protein implicated in fibroblast growth factor receptor signaling. Proc Natl Acad Sci USA. 95:1998;6903-6908.
94. Shirouzu M et al. Mutations that abolish the ability of Ha-Ras to associate with Raf-1. Oncogene. 9:1994;2153-2157.
95. Kobe B, Deisenhofer J. The leucine-rich repeat: a versatile binding motif. Trends Biochem Sci. 19:1994;415-421.
96. Culter M, Bassin R, Zanoni L, Talbot N. Isolation of rsp-1, a novel cDNA capable of suppressing v-ras. Mol Cell Biol. 12:1992;3750-3756.
97. Goshima M et al. Characterization of a novel Ras-binding protein Ce-FLI-1 comprising leucine-rich repeats and gelsolin-like domains. Biochem Biophys Res Commun. 257:1999;111-116.
98. Liu YT, Yin HL. Identification of the binding partners for flightless I, A novel protein bridging the leucine-rich repeat and the gelsolin superfamilies. J Biol Chem. 273:1998;7920-7927.
99. Masuelli L, Cutler ML. Increased expression of the Ras suppressor Rsu-1 enhances Erk-2 activation and inhibits Jun kinase activation. Mol Cell Biol. 16:1996;5466-5476.
100. Shibatohge. Identification of PLC210, a Caenorhabditis elegans phospholipase C, as a putative effector of Ras. J Biol Chem. 273:1998;6218-6222.
101. Matsuo T, Takahashi K, Kondo S, Kaibuchi K, Yamamoto D. Regulation of cone cell formation by Canoe and Ras in the developing Drosophila eye. Development. 124:1997;2671-2680.
102. Watari Y et al. Identification of Ce-AF-6, a novel Caenorhabditis elegans protein, as a putative Ras effector. Gene. 224:1998;53-58.